outcome of the Board Meeting

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹44.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-1.0% vs market

Pharmaceuticals peers, median of 157sector-0.0%-1.1% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1-0.1-1.0-0.0-1.1

Next day

-1.1-0.2-1.0-0.4-0.7

-2.7+0.4-3.1-0.3-2.4

-5.0-0.4-4.6-1.0-4.0

-7.5-0.6-6.9-1.3-6.2

-4.5-0.9-3.7-1.5-3.0

-8.0-3.0-5.0-3.2-4.8

15d

-8.2-3.9-4.3-3.4-4.8

-10.7-4.8-5.8-4.0-6.7

-8.3-7.8-0.5-6.6-1.7

-20.9-7.2-13.7-8.5-12.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sandu Pharmaceuticals' board, meeting on 12 November 2025, approved the unaudited standalone financial results for Q2 FY26 and H1 FY26 (ended 30 September 2025). Revenue from operations for Q2 was ₹1,762.11 lakhs, almost flat compared to ₹1,770.49 lakhs in Q2 FY25. H1 FY26 revenue came in at ₹3,432.01 lakhs, marginally lower than ₹3,475.43 lakhs in H1 FY25. Profit after tax for Q2 rose modestly to ₹52.43 lakhs (from ₹50.02 lakhs), while H1 PAT grew about 12% to ₹74.76 lakhs. The statutory auditor (Dileep & Prithvi) issued a clean, unmodified limited review report with no qualifications or emphasis of matter. The company continues to operate in a single segment – Ayurvedic medicines.

Likely market impact

A nearly flat top line but improving profitability and strong operating cash flow of ₹241.84 lakhs suggest stable business performance. Shareholders should view this as a routine quarterly update with no negative flags, though revenue growth remains soft.